Expansion momentum AtomVie is rapidly expanding its radiopharmaceutical manufacturing footprint with a new Hamilton facility development and a recent facility expansion in Independence, Kansas, signaling increased capacity and geographic reach for clinical and commercial radiopharmaceutical supply.

Strategic partnerships Key collaborations include a long term supply agreement with TerraPower Isotopes for actinium-225 and a partnership with Radiopharm Theranostics, highlighting opportunities for co-development and supply coordination across high-value radiopharmaceutical programs.

Leadership and funding Delivery of significant investment and leadership appointments, including a $138 million facility investment, $5 million funding support, and a Chief Business Officer hire, indicate strengthened governance, scale readiness, and sales engagement potential with investors and customers.

Market positioning As a GMP radiopharmaceutical CDMO serving from Phase 1 to commercial launch with global distribution, AtomVie targets high-growth clinical and commercial radiopharma programs, presenting opportunities to capture outsourcing needs from biotech and pharma companies seeking reliable manufacturing and logistics.

Investor and industry visibility Active participation in investor events such as BBHIC 2026 and press coverage around expansions and financing enhances credibility with potential customers seeking proven capabilities, suggesting outreach windows for strategic outreach and partner recruitment.